Oral Anticancer Therapy Start Note

Date: [Encounter date]

Patient: [Patient name and identifiers per institutional convention]

Provider: [Provider name and credentials]

Encounter Type: [in-person / telehealth]

Visit Reason: Start oral anticancer therapy — [new start / restart / new regimen]

Clinical Context

[Cancer diagnosis with histology and relevant biomarkers/drivers; disease stage and current status; line of therapy and treatment intent (curative / disease control / palliative); rationale for regimen selection with guideline/label alignment] (Summarize in 2–4 concise sentences. Note any off-label use or baseline dose modification with reasoning.)

Baseline Assessment

Performance Status: [Status] using [ECOG / Karnofsky / other scale]

Allergies: [Drug allergies and clinically relevant prior reactions]

Pregnancy/Fertility: [Pregnancy status and testing if indicated; fertility preservation discussion status; contraception counseling completed or documented reason not applicable] (Do not omit. If testing pending, document: "pending—do not start until reviewed.")

Baseline Labs: [Relevant labs with dates; confirmation values meet start parameters or specify abnormalities; note any baseline dose adjustments for renal/hepatic function] (If required labs pending, state: "pending—do not start until reviewed.")

Medication Reconciliation: [Prescription, OTC, herbal, and supplement review completed]

Interactions Identified: [Interaction → action taken for each] (If none, state: "No clinically significant interactions identified.")

Regimen Specification

Regimen Name: [Standard protocol name, if applicable]

Drug(s): [Generic name (brand optional), strength/form]

Dose and Schedule: [Dose per administration; frequency; cycle structure including days on/off and cycle length]

Start Date: [Calendar date]

Administration Instructions: [Food requirements; timing; swallowing instructions; missed dose plan; vomited dose instructions]

Dispensing: [Quantity; refills (zero unless explicitly justified); pharmacy channel (internal / specialty)]

Hold Parameters: [Key lab/symptom thresholds for holding therapy or reference to institutional protocol]

Supportive Care: [Prophylactic and supportive medications initiated as regimen-specific]

(For multi-drug regimens, use the table below in place of the single-drug fields above.)

Drug (generic ± brand)	Strength/Form	Dose	Schedule	Administration Instructions	Dispensing
[Drug A]	[Strength/form]	[Dose per administration]	[Days on/off; cycle length]	[Food/timing; missed/vomited dose]	[Qty; refills; channel]
[Drug B]	[Strength/form]	[Dose per administration]	[Days on/off; cycle length]	[Food/timing; missed/vomited dose]	[Qty; refills; channel]

Education and Consent

Informed Consent: [Obtained / Deferred] — [Indication, benefits, risks, and alternatives discussed] (If deferred, document reason and required step before start.)

Education Provided: [Verbal and written materials; language used; interpreter involvement; caregiver participation]

Topics Covered: [Dosing schedule; missed dose plan; drug and food interactions; common and serious side effects; symptoms requiring clinic contact; symptoms requiring ED evaluation; when to hold medication; safe handling and home disposal] (If home disposal not applicable per institutional policy, document accordingly.)

Teach-back: [Patient/caregiver demonstrated understanding / areas needing reinforcement]

Monitoring and Follow-up

Lab Schedule: [Labs, frequency, and duration]

Clinical Monitoring: [Regimen-specific monitoring as applicable]

Adherence Plan: [Identified barriers and supports in place] (If assessment incomplete, document plan and timing to complete.)

Next Appointment: [Date or timeframe]

Escalation Instructions: [How to reach oncology team during and after hours; ED triggers specific to this regimen]